Prime Medicine (PRME) Retained Earnings (2021 - 2026)

Prime Medicine (PRME) has 6 years of Retained Earnings data on file, last reported at $1.0 billion in Q1 2026.

• Quarterly Retained Earnings rose 6761266.67% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 6761266.67% YoY) and the FY2025 annual result came in at -$888.4 million, down 88835500.0% from the prior year.
• Retained Earnings climbed to $1.0 billion in Q1 2026, from -$888.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1.0 billion in Q1 2026 to a low of -$888.4 million in Q4 2025.
• A 5-year average of $953466.7 and a median of -$15000.0 in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2025 — Retained Earnings tumbled 88835500.0% — and 2026, when it jumped 6761266.67%.
• Tracing PRME's Retained Earnings over 5 years: stood at $609.8 million in 2022, then tumbled by 100.0% to -$15000.0 in 2023, then jumped by 106.67% to $1000.0 in 2024, then plunged by 88835500.0% to -$888.4 million in 2025, then surged by 214.16% to $1.0 billion in 2026.
• The last three Retained Earnings figures came in at $1.0 billion (Q1 2026), -$888.4 million (Q4 2025), and $33000.0 (Q3 2025), per Business Quant data.